Reuters logo
BRIEF-Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study
July 10, 2017 / 1:36 PM / 3 months ago

BRIEF-Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study

July 10 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors

* Says majority of adverse events were mild/moderate in severity, with most common ae’s consisting transient, mild injection site reactions

* Says with up to 20 months of dosing, fitusiran safety and tolerability profile remains encouraging in the study

* Says there was one discontinuation in study due to AE, an asymptomatic alanine aminotransferase elevation in patient with hcv infection

* Says expect initial results of atlas phase 3 program in mid-to-late 2019 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below